First New IV and Oral Antibiotic with a Novel Mechanism of Action Approved in Nearly Two Decades Provides Critically Needed Treatment Option for Adult Patients with CABP XENLETA Expected to be Available mid-September 2019 Conference call and webcast today at 4:30 p.m. EDT DUBLIN, Ireland, Aug. 19, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ:...
Category: News
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)
First New IV and Oral Antibiotic with a Novel Mechanism of Action Approved in Nearly Two Decades Provides Critically Needed Treatment Option for Adult Patients with CABP XENLETA Expected to be Available mid-September 2019 Conference call and webcast today at 4:30 p.m. EDT DUBLIN, Ireland, Aug. 19, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ:...
Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection
NDA resubmission anticipated early in the fourth quarter 2019 DUBLIN, Ireland, Aug. 16, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that following its receipt of final Type A Meeting minutes from the U.S. Food and...
Iterum Therapeutics Reports Second Quarter 2019 Financial Results
–Phase 3 Topline Data anticipated in the fourth quarter– — NDA filings expected in first quarter of 2020– DUBLIN, Ireland and CHICAGO, Aug. 14, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat...
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan
Company Initiates Search for New Chief Executive Officer MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes to its board of directors and executive management team. David Gill, a current Melinta...
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan
Company Initiates Search for New Chief Executive Officer MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes to its board of directors and executive management team. David Gill, a current Melinta...
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
~ Revenue of$16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~ ~ Reduction of Operating Expenses of 32 Percent, or $16.3 million, Year-Over-Year ~ ~ Commenced Enrollment in Clinical Trial Evaluating Orbactiv® (oritavancin) Shorter Infusion Time Formulation in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ~...
SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
Significant progress made in Phase 3 VANISH program evaluating oral ibrexafungerp for the treatment of VVC, with NDA submission anticipated in the second half of 2020
Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three and six months ended June 30, 2019 and recent corporate highlights. “Nabriva has made significant advances in the second...
SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
JERSEY CITY, N.J., Aug. 7, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended June 30, 2019, and provided an update on recent clinical developments. “We are pleased with the rapid enrollment observed in our Phase 3 VANISH program...